Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases for which there are no cures.
These diseases are immunopathogenic, and medical treatment is centered on the temperance of a dysregulated immune response to allow mucosal healing and prevent the sequelae of fistulation and stenosis.
Accordingly, the armamentarium of medications, which has expanded immensely in recent history, is not without significant infectious and neoplastic risks.
|Patient registries provide knowledge to calculate the incidence of safety outcomes|
|Inflammatory Bowel Diseases|
Many of these untoward effects can be mitigated by screening and avoidance of contraindicated medications.
Dr Matthew Cohn and colleagues reviewed the cautions for use of immunomodulators, anticytokine, and α4-integrin antagonists.
The researchers noted that potential adverse events are further complicated by substantial heterogeneity in disease phenotype in the inflammatory bowel disease population.
The team large patient registries and databases provide considerable experience, and knowledge to calculate the incidence of safety outcomes.
Dr Cohn's team comments, "To identify rarer outcomes after prolonged therapy, more prospective studies and continued adverse event reporting will aid safe application and minimize potential harms."